N-Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-α Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats

Circulation

Volumn 110, Issue 14, 2004, Pages 2003-2009

  Bourraindeloup, Marie ^a   Adamy, Christophe ^a   Candiani, Gabriele ^a   Cailleret, Michel ^a   Bourin, Marie Claude ^a   Badoual, Thierry ^b   Su, Jin Bo ^b   Adubeiro, Sylviane ^a   Roudot Thoraval, Françoise ^a   Dubois Rande, Jean Luc ^a,b   Hittinger, Luc ^a,b   Pecker, Françoise ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Acetylcysteine; Glutathione; Heart failure; N G nitroarginine methyl ester; Tumor necrosis factor

Indexed keywords

ACETYLCYSTEINE; COLLAGEN; GELATINASE A; GELATINASE B; GLUTATHIONE; N(G) NITROARGININE METHYL ESTER; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SPHINGOMYELIN PHOSPHODIESTERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; COLLAGEN SYNTHESIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HIGH SODIUM INTAKE; HYPERTENSION; MALE; NONHUMAN; PRECURSOR; PRIORITY JOURNAL; RAT; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ECHOGRAPHY; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE; HEART VENTRICLE REMODELING; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; SALT INTAKE; WISTAR RAT;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; COLLAGEN; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; GLUTATHIONE; HEART VENTRICLES; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDIAL CONTRACTION; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; RATS; RATS, WISTAR; SODIUM CHLORIDE, DIETARY; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 4944257151     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000143630.14515.7C     Document Type: Article

References (36)

1. Von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart: pathophysiology and therapeutic implications. Basic Res Cardiol. 2004;99:18-28.
2. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
3. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002;86:123-130.
4. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
5. Liu B, Andrieu-Abadie N, Levade T, et al. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem. 1998;273:11313-11320.
6. Oral H, Dorn GW II, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem. 1997;272:4836-4842.
7. Amadou A, Nawrocki A, Best-Belpomme M, et al. Arachidonic acid mediates dual effect of TNF-alpha on Ca(2+) transients and contraction of adult rat cardiomyocytes. Am J Physiol. 2002;282: C1339-C1347.
8. Cailleret M, Amadou A, Andrieu-Abadie N, et al. W-Acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. Circulation. 2004;109:406-411.
9. Liu B, Hannun YA. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem. 1997;272:16281-16287.
10. Arnal JF, el Amrani AI, Chatellier G, et al. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension. 1993;22:380-387.
11. Yamada SS, Sassaki AL, Fujihara CK, et al. Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Hypertension. 1996;27:1165-1172.
12. Martinez DV, Rocha R, Matsumura M, et al. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension. 2002;39:614-618.
13. Rossi MA, Ramos SG, Prado CM. Chronic inhibition of nitric oxide synthase induces hypertension and cardiomyocyte mitochondrial and myocardial collagen remodelling in the absence of hypertrophy. J Hypertens. 2003;21:993-1001.
14. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969;27:502-522.
15. Preaux AM, Mallat A, Nhieu JT, et al. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology. 1999;30:944-950.
16. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethyl-arginine in humans. Circulation. 2004;109:172-177.
17. Bartunek J, Weinberg EO, Tajima M, et al. Chronic N(G)-nitro-L-arginine methyl ester-induced hypertension: novel molecular adaptation to systolic load in absence of hypertrophy. Circulation. 2000;101:423-429.
18. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy. Lancet. 1990;335:294-295.
19. Levine B, Kaiman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
20. Satoh M, Nakamura M, Saitoh H, et al. Tumor necrosis factor-alpha- converting enzyme and tumor necrosis factor-alpha in human dilated cardiomyopathy. Circulation. 1999;99:3260-3265.
21. Torre-Amione G, Stetson SJ, Youker KA, et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation. 1999;100:1189-1193.
22. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854-2865.
23. Levade T, Auge N, Veldman RJ, et al. Sphingolipid mediators in cardiovascular cell biology and pathology. Circ Res. 2001;89:957-968.
24. Staal FJ, Roederer M, Herzenberg LA. Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA. 1990;87:9943-9947.
25. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 1998;97:1375-1381.
26. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001;104:826-831.
27. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation. 2003;107:926-928.
28. Blankenberg S, Rupprecht HJ, Bickel C, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med. 2003;349:1605-1613.
29. Shiomi T, Tsutsui H, Matsusaka H, et al. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation. 2004;109:544-549.
30. Sochman J. N-Acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know?! J Am Coll Cardiol. 2002;39:1422-1428.
31. Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide Synthesis in rats. Circulation. 2000;101:305-310.
32. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107:992-995.
33. Herzenberg LA, De Rosa SC, Dubs JG, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A. 1997;94:1967-1972.
34. Hauer K, Hildebrandt W, Sehl Y, et al. Improvement in muscular performance and decrease in tumor necrosis factor level in old age after antioxidant treatment. J Mol Med. 2003;81:118-125.
35. Ritter O, Neyses L. The molecular basis of myocardial hypertrophy and heart failure. Trends Mol Med. 2003;9:313-321.
36. Linseman JV, Bristow MR. Drug therapy and heart failure prevention. Circulation. 2003;107:1234-1236.